| abstract |
The present invention relates to a novel group of halogen-substituted 4-phenyl-1-piperazinyl, piperidinyl, and tetrahydropyridyl derivatives having affinity for dopamine D4 receptors and D3 receptors. The compounds of the invention can be used to treat certain psychiatric and neurological disorders, including psychosis. In the compounds of the present invention, W is a carbon atom or a nitrogen atom or a methine group, and refers to a dotted line chemical bond from W when W is a carbon atom and does not represent a chemical bond when W is nitrogen or methine; R 1 and R 2 are independently hydrogen or halogen, with the proviso that at least one of R 1 and R 2 is halogen; R3 is hydrogen or halogen or alkyl, alkenyl, alkynyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, hydroxy, amino, alkylamino, dialkylamino, nitro or cyano; n is 2, 3, 4 or 5; X is oxygen or sulfur or carbonyl, thiocarbonyl, methylene, sulfinyl or sulfonyl; and Q is a group of formula (II) wherein Z is a 3- or 4-membered chain, wherein the chain members are selected from the group consisting of carbon, nitrogen, methine, methylene, carbonyl, and amine, with the proviso that only one of the chain moieties may be the nitrogen atom or imino group, and the Z chain may optionally contain one or two double bonds; R4, R5, R6, R7, R8 and R9 are independently hydrogen or halogen, or trifluoromethyl, nitro, cyano, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfonyl, hydroxy, hydroxyalkyl; , amino, alkylamino, dialkylamino, acyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl; with the proviso that X is O or S when the Q group is attached via a nitrogen atom. The invention also encompasses pharmaceutical compositions containing the compounds. HE |